
|Videos|July 21, 2022
How Ruxolitinib Will Change the Future of Vitiligo Treatment
Author(s)Kaitlyn Bader, Associate Editor
Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
2
New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Social Media Mythbusters: The Summer Skin Care "Shutdown"
5












